Fenwick & West LLP represented Dermira, Inc., a development-stage biotechnology company focused on developing and commercializing innovative new therapies in dermatology, in its recently announced $35 million Series B financing. The round included participation from new investor Maruho Co., Ltd. and also included existing investors Bay City Capital, New Enterprise Associates and Canaan Partners.
The company plans on utilizing the new funds to continue to advance its robust pipeline of novel therapeutics for serious dermatological conditions.
The Fenwick transaction team was led by corporate partner Douglas Cogen and corporate associates Sheri Wardwell and Michael Brown; and technology transaction partner E.A. Lisa Kenkel.